Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SANA
stocks logo

SANA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.140
-33.38%
--
--
-0.137
-34.92%
--
--
-0.142
-63.67%
Estimates Revision
Stock Price
Go Up
up Image
+75.00%
In Past 3 Month
Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.180
sliders
Low
5.00
Averages
7.00
High
9.00
Current: 5.180
sliders
Low
5.00
Averages
7.00
High
9.00
Citizens JMP
Outperform
maintain
$5 -> $8
2025-10-30
Reason
Citizens JMP
Price Target
$5 -> $8
2025-10-30
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Sana Biotechnology to $8 from $5 and keeps an Outperform rating on the shares. Sana's enhanced Fusogen platform now offers improved specificity and expansion, with an IND filing anticipated in 2026, the analyst tells investors in a research note. Progress across multiple programs, including the modified pancreatic islet cell IST in T1D, the iPSC program nearing IND readiness, and SC291 data expected in 4Q25, combined with a $177.2M pro forma cash position, suggests the shares remain undervalued with potential upside from future Fusogen monetization, Citizens says.
Wedbush
NULL -> Outperform
initiated
$5
2025-09-24
Reason
Wedbush
Price Target
$5
2025-09-24
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Sana Biotechnology with an Outperform rating and $5 price target.
Wedbush
Outperform
initiated
$5
2025-09-24
Reason
Wedbush
Price Target
$5
2025-09-24
initiated
Outperform
Reason
As previously reported, Wedbush initiated coverage of Sana Biotechnology with an Outperform rating and $5 price target. Lead candidate SC451 is an off-the-shelf pancreatic islet cell therapy for type 1 diabetes, which can address the limitations of device-based management and islet cell transplant. A second program, SG299, is an in vivo CART cell therapy candidate which may address the hurdles of cost, lymphodepletion, and access associated with current autologous CAR-T approaches. Both programs may enter the clinic as early as 2026, the firm notes. Wedbush views Sana as holding scarcity value for both its immune evasion and in vivo CART platforms, with substantial long-term growth potential.
Morgan Stanley
Maxwell Skor
Overweight
initiated
$12
2025-07-02
Reason
Morgan Stanley
Maxwell Skor
Price Target
$12
2025-07-02
initiated
Overweight
Reason
Morgan Stanley analyst Maxwell Skor assumed coverage of Sana Biotechnology with an Overweight rating and $12 price target. Six-month data for UP421 in type 1 diabetes show continued cell survival and insulin production without immunosuppression, notes the analyst, who looks forward to an investigational new drug filing for the company's proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451, as early as next year.
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$11
2025-03-18
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$11
2025-03-18
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Reni Benjamin
Hold
to
Buy
Upgrades
$5
2025-03-18
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$5
2025-03-18
Upgrades
Hold
to
Buy
Reason
Citizens JMP upgraded Sana Biotechnology to Outperform from Market Perform with a $5 price target. The firm cites its cash per share and platform value analysis for the upgrade. Sana reported Q4 results and provided corporate updates, including longer follow-up from the Upsala IST demonstrating three-month islet cell viability, the analyst tells investors in a research note. Citizens says that with three-month follow-up from the modified pancreatic islet cell IST program validating the Hypoimmune platform in type 1 diabetes, SC291 data in autoimmune diseases expected in 2025, and a cash position of $152.5M, Sana shares are undervalued.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Sana Biotechnology Inc (SANA.O) is -9.22, compared to its 5-year average forward P/E of -5.25. For a more detailed relative valuation and DCF analysis to assess Sana Biotechnology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.25
Current PE
-9.22
Overvalued PE
-1.83
Undervalued PE
-8.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.54
Undervalued EV/EBITDA
-8.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SANA News & Events

Events Timeline

(ET)
2025-11-06
18:21:04
Sana Biotechnology announces Q3 earnings per share of (16c), below consensus estimate of (19c)
select
2025-10-15 (ET)
2025-10-15
13:43:35
Sana Biotechnology's Strength Linked to EMJ Capital's Long Position
select
link
2025-08-11 (ET)
2025-08-11
16:54:05
Sana Biotechnology reports Q2 EPS (16c), consensus (21c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
11-18NASDAQ.COM
Three Genomics Stocks Worth Adding to Your Portfolio

  • Genomics Overview: Genomics, the study of entire genomes, is gaining traction among pharmaceutical and biotech companies due to advancements in personalized medicine and drug development, distinguishing itself from genetics by focusing on gene interactions and their roles in living systems.

  • Synthetic Biology and Genome Editing: The field of genomics has led to the rise of synthetic biology and genome-editing technologies like CRISPR/Cas9, which allow for precise DNA modifications to treat genetic diseases, with companies like CRISPR Therapeutics and Intellia Therapeutics at the forefront.

  • Market Growth Projections: The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market is expected to grow at a CAGR of 17.30% from 2025 to 2030, indicating significant investment opportunities in these sectors.

  • Company Highlights: Notable companies in the genomics space include Editas Medicine, which is developing gene editing therapies, Sana Biotechnology, focusing on cell engineering for diseases like type 1 diabetes, and Pacific Biosciences, known for advanced sequencing technologies, all showing promising stock performance.

[object Object]
Preview
4.0
11-13NASDAQ.COM
Everything You Should Know About the Upgrade of Sana (SANA) Rating to Buy

  • Sana Biotechnology Upgrade: Sana Biotechnology (SANA) has been upgraded to a Zacks Rank #2 (Buy) due to a positive trend in earnings estimates, indicating potential stock price increases.

  • Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.

  • Earnings Estimates: Analysts have raised their earnings estimates for Sana by 12.8% over the past three months, reflecting an improvement in the company's underlying business.

  • Investment Opportunities: The article highlights the potential for significant investment opportunities in the convergence of artificial intelligence and quantum computing, encouraging investors to consider stocks positioned for growth in this area.

[object Object]
Preview
3.0
11-10Benzinga
"Eric Jackson's Bold Bet on BTQ Technologies: A Quantum Computer That Could 'Compromise All Cryptocurrencies'"

  • Investment Focus: Eric Jackson, founder of EMJ Capital, has identified BTQ Technologies Corp. as a promising investment, viewing it as a critical defense against potential quantum computer threats to cryptocurrency security.

  • Cybersecurity Positioning: Jackson likens BTQ to CrowdStrike in the quantum computing space, emphasizing its role in developing post-quantum cryptography to protect against quantum attacks.

  • Investment Strategy: Jackson's investment philosophy, termed "Rising Dynasty," targets companies with the potential for 100x returns, with BTQ being a key focus alongside other firms like SANA Biotechnology and IREN Ltd.

  • Stock Performance: BTQ's stock has seen significant gains, rising over 124% year-to-date and 3,061.90% over the past year, despite indications of a weaker price trend in the short to long term.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Sana Biotechnology Inc (SANA) stock price today?

The current price of SANA is 5.18 USD — it has increased 15.88 % in the last trading day.

arrow icon

What is Sana Biotechnology Inc (SANA)'s business?

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.

arrow icon

What is the price predicton of SANA Stock?

Wall Street analysts forecast SANA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SANA is 7.00 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Sana Biotechnology Inc (SANA)'s revenue for the last quarter?

Sana Biotechnology Inc revenue for the last quarter amounts to -40.39M USD, decreased -39.95 % YoY.

arrow icon

What is Sana Biotechnology Inc (SANA)'s earnings per share (EPS) for the last quarter?

Sana Biotechnology Inc. EPS for the last quarter amounts to -29470000.00 USD, decreased -47.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Sana Biotechnology Inc (SANA)'s fundamentals?

The market is revising No Change the revenue expectations for SANA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 75.00%.
arrow icon

How many employees does Sana Biotechnology Inc (SANA). have?

Sana Biotechnology Inc (SANA) has 194 emplpoyees as of December 05 2025.

arrow icon

What is Sana Biotechnology Inc (SANA) market cap?

Today SANA has the market capitalization of 1.38B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free